Compugen Ltd.

NasdaqCM:CGEN Stock Report

Market Cap: US$144.0m

Compugen Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Eran Ophir

Chief executive officer

US$478.2k

Total compensation

CEO salary percentage42.05%
CEO tenure5.8yrs
CEO ownershipn/a
Management average tenure5.8yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise

Oct 07
There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Oct 02
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically

May 25
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically

Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?

Apr 09
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?

Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet

Feb 26
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
User avatar

COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain

Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

CEO Compensation Analysis

How has Eran Ophir's remuneration changed compared to Compugen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$28m

Jun 30 2025n/an/a

-US$19m

Mar 31 2025n/an/a

-US$14m

Dec 31 2024US$478kUS$201k

-US$14m

Sep 30 2024n/an/a

US$2m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$541kUS$196k

-US$19m

Compensation vs Market: Eran's total compensation ($USD478.22K) is about average for companies of similar size in the US market ($USD577.67K).

Compensation vs Earnings: Eran's compensation has been consistent with company performance over the past year.

CEO

Eran Ophir (47 yo)

5.8yrs
Tenure
US$478,219
Compensation

Dr. Eran Ophir, Ph D., joined Compugen Ltd. in 2015 and was appointed Vice President of Research and Drug Discovery in March 2020.Dr. Ophir served as Senior Vice President of Research & Drug Discovery at...

Leadership Team

NamePositionTenureCompensationOwnership
Anat Cohen-Dayag
Executive Chair11.8yrsUS$1.24m0.060%
$ 86.4k
Eran Ophir
CEO & Director5.8yrsUS$478.22kno data
Zurit Levine
Senior Vice President of Strategic Collaborations7.9yrsUS$461.80kno data
Pierre Ferre
Senior VP of Preclinical Development & Corporate Operations1.9yrsUS$604.00kno data
Michelle Mahler
Chief Medical Officer1.8yrsUS$592.99kno data
David Silberman
Chief Financial Officer1.3yrsno datano data
Yvonne Naughton
Head of Investor Relations & Corporate Communicationsno datano datano data
Eran Dor
General Counsel & Corporate Secretary6.9yrsno datano data
Dorit Amitay
Vice President of Human Resources18.9yrsno datano data
Yaron Turpaz
Senior VP & Senior Advisor of Data and Informatics Solutions6.1yrsno datano data
Rivka Schwartz
Vice President Research and Discoveryno datano datano data
5.8yrs
Average Tenure
54yo
Average Age

Experienced Management: CGEN's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anat Cohen-Dayag
Executive Chair11.8yrsUS$1.24m0.060%
$ 86.4k
Eran Ophir
CEO & Directorless than a yearUS$478.22kno data
Nils Lonberg
Member of Scientific Advisory Board5.3yrsno datano data
Sanford Zweifach
Independent Director7.5yrsno datano data
Howard Soule
Member of Scientific Advisory Board12.3yrsno datano data
Gilead Halevy
Independent Director7.5yrsno datano data
Kinneret Livnat-Savitzky
Independent Director7.5yrsno datano data
Andrew Pardoll
Chairman of Scientific Advisory Board11.9yrsno datano data
Antoni Ribas
Member of Scientific Advisory Board12.3yrsno datano data
Eran Perry
Independent Director6.4yrsno datano data
Iain McInnes
Member of Scientific Advisory Board12.3yrsno datano data
Miriam Merad
Member of Scientific Advisory Board8.8yrsno datano data
8.1yrs
Average Tenure
58yo
Average Age

Experienced Board: CGEN's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 22:58
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Compugen Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling WangChardan Capital Markets, LLC
Michael KingCitizens JMP Securities, LLC
Christopher HowertonJefferies LLC